UY35818A - Composiciones y métodos para modular los receptores x farnesoides - Google Patents
Composiciones y métodos para modular los receptores x farnesoidesInfo
- Publication number
- UY35818A UY35818A UY0001035818A UY35818A UY35818A UY 35818 A UY35818 A UY 35818A UY 0001035818 A UY0001035818 A UY 0001035818A UY 35818 A UY35818 A UY 35818A UY 35818 A UY35818 A UY 35818A
- Authority
- UY
- Uruguay
- Prior art keywords
- farnesoid
- receptors
- compositions
- modulate
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente invención se relaciona con compuestos de la fórmula I:un estereoisómero, enantiómero, una sal farmacéuticamente aceptable o un conjugado aminoácido del mismo; en donde las variables son como se definen en el presente documento;y sus composiciones farmacéuticas, que son útiles como moduladores de la actividad de los receptores X farnesoides (FXR).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361900013P | 2013-11-05 | 2013-11-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35818A true UY35818A (es) | 2015-05-29 |
Family
ID=51982773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035818A UY35818A (es) | 2013-11-05 | 2014-11-04 | Composiciones y métodos para modular los receptores x farnesoides |
Country Status (42)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| MX364834B (es) | 2013-11-05 | 2019-05-08 | Novartis Ag | Composiciones y metodos para modular los receptores x farnesoides. |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2016174616A1 (en) * | 2015-04-30 | 2016-11-03 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors |
| HUE054819T2 (hu) | 2016-02-22 | 2021-10-28 | Novartis Ag | Eljárások FXR agonista alkalmazására |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
| KR20210110407A (ko) * | 2016-09-14 | 2021-09-07 | 노파르티스 아게 | Fxr 작용제의 신규 요법 |
| JOP20190040A1 (ar) * | 2016-09-14 | 2019-03-10 | Novartis Ag | توليفة من ناهضات fxr |
| AU2017339826A1 (en) * | 2016-10-05 | 2019-04-04 | Novartis Ag | Combination compositions comprising FXR agonists for treating or preventing a fibrotic,cirrhotic disease or disorder |
| CN107973790A (zh) * | 2016-10-22 | 2018-05-01 | 合帕吉恩治疗公司 | 杂环fxr调节剂 |
| PL3600309T3 (pl) | 2017-03-28 | 2022-11-07 | Gilead Sciences, Inc. | Skojarzenia terapeutyczne do leczenia chorób wątroby |
| JP7184302B2 (ja) * | 2017-06-05 | 2022-12-06 | ナショナル ユニバーシティー オブ シンガポール | ヒトトレフォイル因子３の阻害に有用な化合物 |
| WO2019034690A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| TW201910317A (zh) | 2017-08-15 | 2019-03-16 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| CN111093705A (zh) * | 2017-09-13 | 2020-05-01 | 诺华股份有限公司 | 包含fxr激动剂的组合 |
| CN110128432B (zh) * | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| CN112424207B (zh) | 2018-07-25 | 2024-03-19 | 诺华股份有限公司 | Nlrp3炎性小体抑制剂 |
| CA3124702A1 (en) | 2019-01-15 | 2020-07-23 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| US10610280B1 (en) | 2019-02-02 | 2020-04-07 | Ayad K. M. Agha | Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| TW202122078A (zh) | 2019-09-06 | 2021-06-16 | 瑞士商諾華公司 | 使用lta4h抑制劑治療肝臟疾病之方法 |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists to treat hepatitis d virus infection |
| CN113387828A (zh) * | 2020-03-14 | 2021-09-14 | 江巨东 | 一种阿利克仑中间体的制备方法 |
| WO2022037663A1 (zh) * | 2020-08-21 | 2022-02-24 | 苏州晶云药物科技股份有限公司 | 苯甲酸衍生物的新晶型及其制备方法 |
| AU2022209084A1 (en) | 2021-01-14 | 2023-08-10 | Centre Leon Bérard | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| US20240067627A1 (en) | 2022-08-03 | 2024-02-29 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050143449A1 (en) * | 2002-11-15 | 2005-06-30 | The Salk Institute For Biological Studies | Non-steroidal farnesoid X receptor modulators and methods for the use thereof |
| CA2651378C (en) * | 2006-05-24 | 2012-08-28 | Eli Lilly And Company | Fxr agonists |
| JP2010504032A (ja) * | 2006-09-15 | 2010-02-04 | タレス アビオニクス インコーポレイテッド | 航空機との間でコンテンツを無線で転送するシステム及び方法 |
| TW200906823A (en) * | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| MX364834B (es) | 2013-11-05 | 2019-05-08 | Novartis Ag | Composiciones y metodos para modular los receptores x farnesoides. |
| WO2016174616A1 (en) | 2015-04-30 | 2016-11-03 | Novartis Ag | Fused tricyclic pyrazole derivatives useful for modulating farnesoid x receptors |
-
2014
- 2014-11-04 MX MX2016005865A patent/MX364834B/es active IP Right Grant
- 2014-11-04 DK DK14803001.8T patent/DK3065738T3/en active
- 2014-11-04 TR TR2018/07321T patent/TR201807321T4/tr unknown
- 2014-11-04 ES ES14803001.8T patent/ES2670984T3/es active Active
- 2014-11-04 PT PT148030018T patent/PT3065738T/pt unknown
- 2014-11-04 NZ NZ719078A patent/NZ719078A/en not_active IP Right Cessation
- 2014-11-04 CA CA2927705A patent/CA2927705C/en active Active
- 2014-11-04 CN CN201480058975.8A patent/CN105682656B/zh not_active Expired - Fee Related
- 2014-11-04 TW TW103138253A patent/TWI662027B/zh not_active IP Right Cessation
- 2014-11-04 CU CU2016000063A patent/CU24375B1/es unknown
- 2014-11-04 PE PE2016000596A patent/PE20160682A1/es unknown
- 2014-11-04 SG SG11201603026PA patent/SG11201603026PA/en unknown
- 2014-11-04 EA EA201690930A patent/EA030430B1/ru not_active IP Right Cessation
- 2014-11-04 MA MA39088A patent/MA39088B1/fr unknown
- 2014-11-04 HU HUE14803001A patent/HUE039155T2/hu unknown
- 2014-11-04 EP EP14803001.8A patent/EP3065738B1/en active Active
- 2014-11-04 BR BR112016009630-4A patent/BR112016009630B1/pt not_active IP Right Cessation
- 2014-11-04 SI SI201430692T patent/SI3065738T1/en unknown
- 2014-11-04 TN TN2016000143A patent/TN2016000143A1/en unknown
- 2014-11-04 PL PL14803001T patent/PL3065738T3/pl unknown
- 2014-11-04 US US15/034,280 patent/US9682939B2/en active Active
- 2014-11-04 JP JP2016552453A patent/JP6424231B2/ja active Active
- 2014-11-04 AP AP2016009165A patent/AP2016009165A0/en unknown
- 2014-11-04 MY MYPI2016701351A patent/MY175903A/en unknown
- 2014-11-04 UY UY0001035818A patent/UY35818A/es not_active Application Discontinuation
- 2014-11-04 KR KR1020167014613A patent/KR102350357B1/ko active IP Right Grant
- 2014-11-04 LT LTEP14803001.8T patent/LT3065738T/lt unknown
- 2014-11-04 AU AU2014346919A patent/AU2014346919B2/en not_active Ceased
- 2014-11-04 RS RS20180524A patent/RS57179B1/sr unknown
- 2014-11-04 WO PCT/US2014/063948 patent/WO2015069666A1/en active Application Filing
- 2014-11-05 JO JOP/2014/0318A patent/JO3454B1/ar active
- 2014-11-05 AR ARP140104163A patent/AR098316A1/es unknown
-
2015
- 2015-03-17 NO NO15712554A patent/NO3105103T3/no unknown
-
2016
- 2016-04-14 ZA ZA2016/02555A patent/ZA201602555B/en unknown
- 2016-04-20 IL IL245242A patent/IL245242B/en active IP Right Grant
- 2016-04-25 CL CL2016000982A patent/CL2016000982A1/es unknown
- 2016-04-26 PH PH12016500777A patent/PH12016500777B1/en unknown
- 2016-05-05 SV SV2016005192A patent/SV2016005192A/es unknown
- 2016-05-05 CR CR20160212A patent/CR20160212A/es unknown
- 2016-05-05 GT GT201600085A patent/GT201600085A/es unknown
-
2017
- 2017-05-18 US US15/598,734 patent/US10077240B2/en active Active
-
2018
- 2018-05-23 HR HRP20180817TT patent/HRP20180817T1/hr unknown
- 2018-05-24 CY CY20181100557T patent/CY1120273T1/el unknown
- 2018-08-07 US US16/056,881 patent/US10683271B2/en active Active
-
2020
- 2020-04-21 US US16/854,762 patent/US11021446B2/en active Active
-
2021
- 2021-04-21 US US17/236,596 patent/US20210253534A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| UY33815A (es) | Composiciones y métodos para modular el fxr | |
| CR20160564A (es) | Dinucleótidos cíclicos como moduladores de sting | |
| GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
| CO2018000589A2 (es) | Oxiesteroles y composiciones farmacéuticas que los contienen | |
| CR20160191A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 | |
| CR20160119A (es) | Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística | |
| DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
| DOP2015000054A (es) | Derivados de c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| UY35143A (es) | Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g | |
| EA201590953A1 (ru) | Пирролидиновые модуляторы gpr40 | |
| EA201590951A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| EA201590949A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| DOP2017000034A (es) | Compuestos de imidazopiridazina | |
| EA201591815A1 (ru) | Бицикло [2.2.2] кислоты - модуляторы gpr120 | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
| CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| ECSP14011505A (es) | Derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| UY35792A (es) | Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220307 |